Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Retina > Several common autoimmune disorders linked with increased odds of AMD
  • Retina

Several common autoimmune disorders linked with increased odds of AMD

Rob Oconnell

Although most autoimmune diseases do not affect the odds of developing AMD, several common autoimmune disorders, such as discoid lupus erythematosus, systemic lupus erythematosus (SLE), Sjogren’s syndrome, and Crohn’s disease, were associated with modestly increased odds of age-related macular degeneration (AMD), according to findings from a recent study. Further research is needed to validate and investigate the underlying mechanisms of these associations, noted the researchers.

Several studies have demonstrated that the pathogenic elements of AMD resemble those of autoimmune diseases, yet the association between AMD development and most autoimmune diseases is unknown. A case-control analysis of patients ages 55 and older with new-onset International Classification of Diseases (ICD) coding of dry, wet, or unspecified AMD between 2005 and 2019 in the Merative MarketScan Commercial and Medicare Databases was conducted. The diagnosis of an autoimmune disease was defined by an outpatient or inpatient claim with a relevant ICD code in the 12 months before the index visit. Conditional multivariable logistic regression, adjusted for AMD risk factors, was used to calculate odd ratios and 95% confidence intervals.

Researchers identified 415,027 cases with new-onset ICD coding for AMD matched with propensity scores to 414,853 controls. In total, 16.1% of cases and 15.9% of controls were diagnosed with any autoimmune disease. The diagnosis of any autoimmune disease did not affect the odds of new-onset ICD coding for AMD in multivariable regression. Discoid lupus erythematosus, SLE, giant cell arteritis, Sjogren’s syndrome, and Crohn’s disease increased the odds of a new-onset ICD coding for AMD.

Reference:
Moir J, Hyman MJ, Wang J, et al. Associations between autoimmune disease and the development of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2023;64(15):45. doi:10.1167/iovs.64.15.45

Share

Related Content

  • Retina

Aflibercept 8 mg shows comparable IOP safety to 2 mg through 96 weeks

  • Retina

Heidelberg receives FDA clearance for updated SPECTRALIS software

  • Retina

Aflibercept 8 mg demonstrates favorable safety profile in large nAMD cohort

  • Retina

Aflibercept 8 mg shows modest benefits in difficult-to-treat nAMD cases

  • Retina

AXPAXLI meets superiority endpoint in SOL-1 Phase 3 wet AMD trial

  • Diabetic Macular Edema

Hawaiian Eye Meeting update: TKI therapy may reduce treatment burden in DME and wet AMD

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon